121 related articles for article (PubMed ID: 29096869)
1. Prospective crossover study for a standardized comparison of the dextrane sulfate whole blood and plasma apheresis system in patients with cardiovascular disease and severe dyslipidemia.
Ramlow W; Prophet H; Waitz G
Atheroscler Suppl; 2017 Nov; 30():99-107. PubMed ID: 29096869
[TBL] [Abstract][Full Text] [Related]
2. Effects of two whole blood systems (DALI and Liposorber D) for LDL apheresis on lipids and cardiovascular risk markers in severe hypercholesterolemia.
Otto C; Berster J; Otto B; Parhofer KG
J Clin Apher; 2007; 22(6):301-5. PubMed ID: 17935245
[TBL] [Abstract][Full Text] [Related]
3. How to optimize lipoprotein apheresis treatment--a second look.
Schettler V; Neumann CL; Hagenah GC; Schulz EG; Wieland E
Atheroscler Suppl; 2013 Jan; 14(1):89-92. PubMed ID: 23357148
[TBL] [Abstract][Full Text] [Related]
4. Low-density lipoprotein apheresis using the Liposorber dextran sulfate cellulose system for patients with hypercholesterolemia refractory to medical therapy.
Gordon BR; Saal SD
J Clin Apher; 1996; 11(3):128-31. PubMed ID: 8915816
[TBL] [Abstract][Full Text] [Related]
5. Efficacy, safety, and tolerability of long-term lipoprotein apheresis in patients with LDL- or Lp(a) hyperlipoproteinemia: Findings gathered from more than 36,000 treatments at one center in Germany.
Heigl F; Hettich R; Lotz N; Reeg H; Pflederer T; Osterkorn D; Osterkorn K; Klingel R
Atheroscler Suppl; 2015 May; 18():154-62. PubMed ID: 25936320
[TBL] [Abstract][Full Text] [Related]
6. Specific Lp(a) apheresis: A tool to prove lipoprotein(a) atherogenicity.
Pokrovsky SN; Afanasieva OI; Safarova MS; Balakhonova TV; Matchin YG; Adamova IYU; Konovalov GA; Ezhov MV
Atheroscler Suppl; 2017 Nov; 30():166-173. PubMed ID: 29096833
[TBL] [Abstract][Full Text] [Related]
7. Association of lipoprotein(a) level with short- and long-term outcomes after CABG: The role of lipoprotein apheresis.
Ezhov MV; Afanasieva OI; Il'ina LN; Safarova MS; Adamova IY; Matchin YG; Konovalov GA; Akchurin RS; Pokrovsky SN
Atheroscler Suppl; 2017 Nov; 30():187-192. PubMed ID: 29096836
[TBL] [Abstract][Full Text] [Related]
8. Low density lipoprotein apheresis in treatment of hyperlipidemia: experience with four different technologies.
Bambauer R; Schiel R; Latza R
Ther Apher; 2000 Jun; 4(3):213-7. PubMed ID: 10910023
[TBL] [Abstract][Full Text] [Related]
9. Actual situation of lipoprotein apheresis in Saxony in 2013.
Emmrich U; Hohenstein B; Julius U
Atheroscler Suppl; 2015 May; 18():215-25. PubMed ID: 25936329
[TBL] [Abstract][Full Text] [Related]
10. The lipid- and lipoprotein- [LDL-Lp(a)] apheresis techniques. Updating.
Stefanutti C; Morozzi C; Perrone G; Di Giacomo S; Vivenzio A; D'Alessandri G
G Chir; 2012; 33(11-12):444-9. PubMed ID: 23140934
[TBL] [Abstract][Full Text] [Related]
11. [Kinetics of lipids and lipoproteins with determination of the recovery rate in the non-steady state following plasma, membrane filtration and dextran sulfate adsorption apheresis in hypercholesterolemia].
Schwartzkopff W; Gräfenhahn H; Nold A; von Baeyer H; Bimmermann A; Schleicher J
Biomed Tech (Berl); 1989 Oct; 34(10):232-42. PubMed ID: 2479419
[TBL] [Abstract][Full Text] [Related]
12. Current insights into the German lipoprotein apheresis standard: PCSK9-inhibitors, lipoprotein apheresis or both?
Schettler VJJ; Ringel J; Jacob S; Julius U; Klingel R; Heigl F; Roeseler E; Grützmacher P;
Atheroscler Suppl; 2017 Nov; 30():44-49. PubMed ID: 29096860
[TBL] [Abstract][Full Text] [Related]
13. Apheresis technologies for prevention and regression of atherosclerosis: clinical results.
Bambauer R; Schneidewind JM; Latza R
ASAIO J; 1999; 45(5):403-7. PubMed ID: 10503615
[TBL] [Abstract][Full Text] [Related]
14. Current insights into the German Lipoprotein Apheresis Registry (GLAR) - Almost 5 years on.
Schettler VJJ; Neumann CL; Peter C; Zimmermann T; Julius U; Roeseler E; Heigl F; Grützmacher P; Blume H;
Atheroscler Suppl; 2017 Nov; 30():50-55. PubMed ID: 29096861
[TBL] [Abstract][Full Text] [Related]
15. Most significant reduction of cardiovascular events in patients undergoing lipoproteinapheresis due to raised Lp(a) levels - A multicenter observational study.
Schatz U; Tselmin S; Müller G; Julius U; Hohenstein B; Fischer S; Bornstein SR
Atheroscler Suppl; 2017 Nov; 30():246-252. PubMed ID: 29096845
[TBL] [Abstract][Full Text] [Related]
16. Long-term experience with extracorporeal low-density lipoprotein cholesterol removal by dextran sulfate cellulose adsorption.
Schulzeck P; Olbricht CJ; Koch KM
Clin Investig; 1992 Feb; 70(2):99-104. PubMed ID: 1600346
[TBL] [Abstract][Full Text] [Related]
17. Lipoprotein apheresis for lipoprotein(a) and cardiovascular disease.
Moriarty PM; Gray JV; Gorby LK
J Clin Lipidol; 2019; 13(6):894-900. PubMed ID: 31753721
[TBL] [Abstract][Full Text] [Related]
18. Comparison of different low density lipoprotein apheresis machines on brain natriuretic Peptide levels in patients with familial hypercholesterolemia.
Moriarty P; Sosland R; Gibson C; Belmont J
Ther Apher Dial; 2010 Feb; 14(1):74-8. PubMed ID: 20438521
[TBL] [Abstract][Full Text] [Related]
19. The first results demonstrating efficiency and safety of a double-column whole blood method of LDL-apheresis.
Hequet O; Le QH; Rigal D; Mekhloufi F; Jaeger S; Sassolas A; Groisne L; Moulin P
Transfus Apher Sci; 2010 Feb; 42(1):3-10. PubMed ID: 19932056
[TBL] [Abstract][Full Text] [Related]
20. The German Lipoprotein Apheresis Registry (GLAR) - almost 5 years on.
Schettler VJJ; Neumann CL; Peter C; Zimmermann T; Julius U; Roeseler E; Heigl F; Grützmacher P; Blume H; Vogt A;
Clin Res Cardiol Suppl; 2017 Mar; 12(Suppl 1):44-49. PubMed ID: 28233268
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
